1] Division of Bone and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA [2] Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Bone Marrow Transplant. 2013 Oct;48(10):1317-23. doi: 10.1038/bmt.2013.116. Epub 2013 Aug 12.
Cryptogenic organizing pneumonia (COP), previously known as bronchiolitis obliterans organizing pneumonia (BOOP), is a significant complication after allogeneic hematopoietic SCT (HCT). However, the pathogenesis of this complication has not yet been elucidated. Therefore, we identified the pre-transplant risk factors for the development of COP/BOOP using the Japan transplant registry database between 2005 and 2009. Among 9550 eligible recipients, 193 experienced COP/BOOP (2%). HLA disparity (odds ratio (OR) 1.51, P=0.05), female-to-male HCT (OR 1.53, P=0.023), and PBSC transplant (OR 1.84, P=0.0076) were significantly associated with an increased risk of COP/BOOP. On the other hand, BU-based myeloablative conditioning (OR 0.52, P=0.033), or fludarabine-based reduced-intensity conditioning (OR 0.50, P=0.0011) in comparison with a TBI-based regimen and in vivo T-cell depletion (OR 0.46, P=0.055) were associated with a lower risk. Of the 193 patients with COP/BOOP, 77 died, including non-relapse death in 46 (59%). Pulmonary failure and fatal infection accounted for 41% (n=19) and 26% (n=12) of the non-relapse death. Allogeneic immunity and conditioning toxicity could be associated with COP/BOOP. Prospective studies are required to elucidate the true risk factors for COP/BOOP and to develop a prophylactic approach.
特发性机化性肺炎(COP),以前称为闭塞性细支气管炎伴机化性肺炎(BOOP),是异基因造血干细胞移植(HCT)后的一种严重并发症。然而,其发病机制尚未阐明。因此,我们使用 2005 年至 2009 年日本移植登记数据库,确定了 COP/BOOP 发生的移植前危险因素。在 9550 名合格的受者中,193 名发生 COP/BOOP(2%)。HLA 错配(比值比(OR)1.51,P=0.05)、女性对男性 HCT(OR 1.53,P=0.023)和 PBSC 移植(OR 1.84,P=0.0076)与 COP/BOOP 的风险增加显著相关。另一方面,与基于 TBI 的方案相比,BU 为基础的清髓性预处理(OR 0.52,P=0.033)或氟达拉滨为基础的降低强度预处理(OR 0.50,P=0.0011)以及体内 T 细胞耗竭(OR 0.46,P=0.055)与较低的风险相关。在 193 例 COP/BOOP 患者中,77 例死亡,包括 46 例(59%)非复发死亡。呼吸衰竭和致命感染分别占非复发死亡的 41%(n=19)和 26%(n=12)。同种异体免疫和预处理毒性可能与 COP/BOOP 相关。需要前瞻性研究来阐明 COP/BOOP 的真正危险因素,并制定预防方法。